Vancomycin-Resistant Enterococcal Infections

Trends in antimicrobial resistance among clinical isolates of enterococci in a Brazilian tertiary hospital: a 4-year study

“…Intrinsic or acquired resistance to various commonly used antimicrobial agents is a remarkable characteristic of enterococci 4 . Acquired resistance to glycopeptides (vancomycin and teicoplanin), penicillins and aminoglycosides (high-level resistance) are the most clinically important, because therapeutic options in these cases are limited.…”

“…Clinical vancomycin-resistant enterococci (VRE) isolates were first recognized in the 1980s in Europe and USA 4 . Approximately ten years later, the first VRE were isolated in Brazil, in the States of Paraná and São Paulo, located in the southern and southeastern regions of the country, respectively 6,7 .…”

Rectal culture screening for vancomycin-resistant enterococcus in chronic haemodialysis patients: false-negative rates and duration of colonisation

“…1 Patients with VRE infections, as well as asymptomatically colonised patients, may serve as a reservoir for the transmission of VRE to other patients. 1 Because dialysis-dependent patients have extensive contact with the healthcare system, they are often in close proximity to other VRE reservoirs. In addition, these patients often receive repeated, prolonged courses of antibiotics, including vancomycin, and frequently have multiple comorbid conditions.…”

“…3,4 Since there is no effective antimicrobial therapy for VRE colonisation, strong efforts have been made to screen for VRE and isolate carriers when detected. 1 To prevent the spread of VRE, many guidelines recommend that healthcare providers use contact precautions during the care of colonised and infected patients until it can be demonstrated that they are no longer colonised. 5 Little is known about the persistence of VRE colonisation in patients with ESRD on haemodialysis treatment.…”

Les entérocoques résistants aux glycopeptides

“…leclercq-r@chu-caen.fr (vancomycine, teicoplanine) constitue une option thérapeutique de choix pour le traitement des infections dues à ces germes. Les entérocoques sont naturellement sensibles à la vancomycine (CMI 1 modale de 1 mg/l) et à la teicoplanine (CMI modale de 0,5 mg/l), si on excepte les deux espèces naturellement résistantes à la vancomycine, E. gallinarum et E. casseliflavus [4]. Les premières souches d'entéro-coques résistantes aux glycopeptides (ERG) ont été décrites à la fin des années 1980 en France et en Angleterre.…”